Skip to content
TrialScanner

NCT05277402

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Phase 1CompletedADAGLeadMRKCollaborator

Registry record

Lead sponsor
Adagene Inc
Conditions
Advanced/Metastatic Solid Tumors
Primary completion
Aug 1, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05277402 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05277402: ADG116 in Combination With... | TrialScanner